Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Overlaying Growth by Business Provide
TAIPEI, TAIWAN – Media OutReach Newswire – 2 July 2026 – Bora Prescription drugs Co., Ltd. (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) right this moment introduced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) together with its biologics drug substance facility in Rockville, Maryland and an related warehousing middle in Frederick, Maryland, for complete consideration of US $122.5 million by its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Settlement with MacroGenics.
With the shut of the transaction, Bora Group’s biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capability throughout two energetic US websites: Rockville, Maryland and San Diego, California, and one growth facility in Zhubei, Taiwan.
“This acquisition establishes a US biologics manufacturing platform that sponsors can rely on, from growth by licensed business provide,” stated Bobby Sheng, Chairman and CEO of Bora Group. “As regulatory and provide chain dynamics proceed to evolve, we count on biotech and pharmaceutical firms to more and more search manufacturing companions with US-based, inspection-proven infrastructure. Bora Biologics is designed to satisfy that want, providing a completely built-in, end-to-end biologics platform spanning drug substance and drug product capabilities.”
With the addition of the Rockville facility, Bora Biologics helps greater than 4 energetic business packages, with greater than 120 accomplished GMP batches and provide into a number of world markets together with the US, EU, Japan, Canada and the UK with absolutely built-in QC and analytical capabilities.
Throughout its US community, Bora Biologics has accomplished 5 FDA inspections, together with two at Rockville and one PMDA evaluation in 2025, with clear outcomes at each websites. The mixed platform has supported greater than 33 biologics and 15 biosimilars, establishing a producing base for biotech and pharmaceutical firms with decreased offshore dependency and domestically anchored infrastructure.
Bora Group intends to combine its US drug substance (DS) capabilities with its present sterile drug product (DP) capabilities over the following 12 to 18 months, providing a seamless, absolutely built-in development-through-commercial biologics answer.
Hashtag: #BoraPharmaceuticals
The issuer is solely answerable for the content material of this announcement.
About Bora
Based in 2007, Bora Prescription drugs (“Bora” or “the Firm”, 6472.TW and BORAY.OTCQX) is a number one pharmaceutical providers firm with a imaginative and prescient and aim of “Contributing to Higher Well being All Over the World”. Working beneath a “Twin Engine” mannequin that integrates CDMO and business experience, we empower pharmaceutical and biotech companions to optimize product growth, speed up launches, and scale provide to satisfy world affected person wants. On the similar time, we actively broaden R&D and gross sales infrastructure, specializing in area of interest and uncommon illness markets to enhance sufferers’ high quality of life.
By investing in expertise, infrastructure, and biologics growth, Bora continues to remodel operations and obtain sustainable progress. Dedicated to creating success “sure,” Bora units new requirements within the pharmaceutical and CDMO industries.
For extra, please go to: 
https://www.bora-corp.com https://www.boracdmo.com
Disclaimer:
This doc and the accompanying info might include forward-looking statements. All statements concerning the corporate’s future enterprise operations, potential occasions, and prospects (together with however not restricted to forecasts, targets, estimates, and operational plans) are thought of forward-looking statements until they discuss with factual occurrences. Ahead-looking statements are topic to varied components and uncertainties which will trigger important variations from precise outcomes, together with however not restricted to cost fluctuations, precise demand, change price variations, market share, aggressive situations, modifications within the authorized, monetary, and regulatory framework, worldwide financial and monetary market situations, political dangers, value estimates, and different dangers and variables past the corporate’s management. These forward-looking statements are based mostly on present predictions and assessments, and the corporate disclaims any duty for future updates.
